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A b s T r A C T
background: results from studies conducted in the 
late 1980s and early 1990s showed that gastrointestinal 
symptoms were common among the general population. 
Meanwhile, lifestyle habits have changed and important 
treatment options have been introduced. This might have 
influenced symptom prevalence. 
Methods: This study aimed to describe the current prevalence 
of upper and lower gastrointestinal symptoms within the 
general population. for this purpose, a demographically 
representative sample of the dutch population within the city 
of Nijmegen and surrounding areas was selected after careful 
comparison with demographic figures from a government 
demographic database. Participants were invited to fill 
in a valid self-report questionnaire about gastrointestinal 
symptoms and prevalence figures were calculated. 
results: A total of 5000 questionnaires was sent and 1616 (32%) 
were returned. of these, 839 (52%) subjects reported having 
had upper (43%) or lower (38%) gastrointestinal symptoms in 
the past four weeks. The most prevalent individual symptoms 
reported were flatulence (47%), abdominal rumbling (40%), 
bloating (37%), alternating solid and loose stools (31%), belching 
(25%) and postprandial fullness (25%). People who smoked 
or used a proton pump inhibitor had an increased risk for 
reporting upper as well as lower gastrointestinal symptoms 
(or 1.99; 95% Ci 1.56 to 2.55, and or 1.37; 95% Ci 1.01 to 1.75, 
respectively for smoking; and or 3.17; 95% Ci 2.17 to 4.72, and 
or 2.14; 95% Ci 1.49 to 3.08, respectively for PPis).
Conclusion: both upper and lower gastrointestinal 
symptoms are very common in a representative sample of 
a general Western population. 
K E Y W o r d s
Dyspepsia, epidemiology, gastrointestinal diseases, 
gastrointestinal symptoms
i N T r o d U C T i o N
Gastrointestinal symptoms are very common in the 
general population and a frequent reason for consulting a 
healthcare professional.1 In 1989, it was shown that 38% 
of an English population reported dyspeptic symptoms.2 
When this study was expanded over five other regions 
in England and Scotland, prevalence of dyspepsia over a 
six-month period was 41%.3 In another random sample of 
older (aged 65-93 years) Minnesota inhabitants, studied 
in 1992, similar results were obtained.4 In addition, a 
prevalence ranging from 10 to 25% was observed for 
lower abdominal symptoms, such as constipation and 
diarrhoea. 
No recent data on the prevalence of gastrointestinal 
symptoms in a general population are available. Since 
these studies were conducted, there have been significant 
changes in lifestyle habits, treatment options, and 
socioeconomic and cultural factors, influencing upper 
as well as lower gastrointestinal symptoms. The most 
prominent changes were probably the introduction of 
proton pump inhibitors (PPIs) and strategies to eradicate 
Helicobacter pylori in national and international guidelines 
for the treatment of patients with upper gastrointestinal 
symptoms. Subsequently, infection rates of H. pylori 
have decreased, whereas the number of prescriptions 
for PPIs has increased dramatically.5,6 Secondly, the use 
of gastro-toxic drugs, such as NSAIDs, has risen and 
gastro intestinal symptoms induced by these drugs are 
increasing.7 Thirdly, the prevalence of overweight and 
obesity is increasing. A high body mass index, and the 
lifestyle habits that precede that, are associated with the 
development of both upper and lower gastrointestinal 
symptoms, such as regurgitation, gastro-oesophageal 
reflux and altered bowel movements.8 
These developments strengthened the need for data on 
the current prevalence of gastrointestinal symptoms in the 
general population. Indeed, a more recent study has shown 
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that, although there is great inter-country variability (46% 
in Mexico, 10% in Japan), abdominal cramping and pain 
are still common in a general population.9 Similar results 
were obtained in the Kalixanda study from Northern 
Sweden, in which the prevalence of predominantly reflux 
symptoms over a three-month period was found to be 
about 40%.10,11 
Although both studies indicate that upper gastrointestinal 
symptoms are still a frequent phenomenon among the 
general population, they were conducted in specific 
populations and investigated specific symptom complexes. 
This study aims to investigate the prevalence of a broad 
range of both upper and lower gastrointestinal symptoms 
in a representative sample of the general population.
P A T i E N T s  A N d  M E T H o d s
subjects
Questionnaires were spread door-to-door in the city of 
Nijmegen and the Nijmegen area. Data from Statistics 
Netherlands (CBS) were used to select neighbourhoods 
that matched the general Dutch population for social 
economic status, age, property value, racial configuration 
and household configuration. One person over the age of 
18 per household was asked to fill in the questionnaire and 
return it by mail. It was specifically mentioned that the 
questionnaire should also be completed if gastrointestinal 
symptoms were absent.
Questionnaire
The questionnaire contained items on demographics, 
lifestyle habits and current medication use. Severity of 
gastrointestinal symptoms in the past four weeks was 
assessed using a valid self-report questionnaire. This 
questionnaire has been extensively used before12-15 and 
symptoms include upper abdominal pain, epigastric pain, 
heartburn, regurgitation, abdominal rumbling, bloating, 
nausea, empty feeling in the stomach, early satiety, 
postprandial fullness, belching, flatulence, haematemesis, 
dysphagia, questions on defecation and foetor ex ore. 
Subjects were asked to rate the severity of gastrointestinal 
symptoms on a seven-point Likert scale (0 = absent; 1 = 
hardly any; 2 = mild; 3 = moderate; 4 = moderately severe; 
5 = severe and 6 = very severe). In analysis a score of 2 or 
higher was defined as symptom presence. Questionnaires 
returned without any of the questions answered were not 
taken into further analysis.
statistical analysis
Statistical analysis was performed using SAS statistical 
software (version 8.2). Data on symptom frequencies were 
summarised using descriptive statistics. Participants 
reporting three or more of the following symptoms: 
epigastric pain, heartburn, regurgitation, abdominal 
rumbling, bloating, empty feeling, nausea, vomiting, early 
satiety, postprandial fullness, belching, haematemesis, 
dysphagia and foetor ex ore, were defined as having upper 
gastrointestinal symptoms. Having three or more of these 
symptoms was defined as having lower gastro intestinal 
symptoms. Alcohol abuse was defined as drinking ≥14 
units/week for women and ≥21 units/week for men 
(National Drug Monitor Netherlands/Trimbos Institute), 
and coffee abuse was defined as the consumption of ≥6 
units/day.16 Any consumption of cigarettes or cigars was 
defined as current smoking. Body mass index (BMI) 
was calculated as the weight in kilograms divided by the 
square of the height in metres (kg/m2), classifications 
were made according to WHO standards: a BMI ≤18.5 = 
underweight, a BMI 18.5 to 25 = normal and a BMI ≥25 
= overweight.17 Comparison of symptom frequencies 
between genders was done using Pearson’s x2 analysis, and 
Pearson’s correlation coefficient was calculated to assess 
the correlation between age and number of symptoms. To 
adjust for multiple testing, a p value <0.01 was considered 
statistically significant. Logistic regression analysis was 
used to assess adjusted odds ratios in order to identify risk 
factors for upper or lower gastrointestinal symptoms.
r E s U l T s
A total of 5000 questionnaires were distributed and 1616 
were returned (32%). Mean age of the responders was 52.3 
years (±17.2) and 34% of the responders were male (table 1). 
Eighty percent of all subjects reported having had at least 
one gastrointestinal symptom in the past four weeks. The 
most frequently reported upper gastro intestinal symptoms 
were bloating (37%), belching (25%), postprandial fullness 
(25%) and heartburn (21%). Lower gastrointestinal 
symptoms most frequently reported were flatulence (47%), 
Table 1. Population demographics (n=1616)
Mean age ±SD 52.3 ± 17.2
Male gender, n (%) 549 (34%)
Non-Western European origin, n (%) 104 (6.4)
BMI, n (%):
<18.5• 
(18.5-25)• 
≥25• 
33 (2.0)
814 (50.4)
704 (43.6)
Smoking, n (%) 385 (24.0)
Alcohol abuse, n (%) 102 (6.3)
Excessive coffee consumption, n (%) 383 (23.7)
Current medication, n (%):
Proton pump inhibitor• 
Aspirin• 
H2-receptor antagonist• 
NSAID• 
134 (8)
165 (10)
17 (1)
66 (4)
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abdominal rumbling (40%), alternating solid and loose 
faeces (31%) and strong urgency (24%) (figures 1 and 2).
Women statistically significantly more often reported 
abdominal pain in general (27 vs 16%), abdominal 
rumbling (42 vs 35%), bloating (41 vs 30%), nausea (20 vs 
9%), early satiety (15 vs 9%), postprandial fullness (27 vs 
20%), constipation (7 vs 18%) and defecation frequently 
with pain (13 vs 7%) than men (all p values <0.01).
In general, 43% of participants reported having had at 
least three upper gastrointestinal symptoms in the past 
four weeks and 38% reported having had at least three 
lower gastrointestinal symptoms. Although proportions of 
subjects with upper and lower gastrointestinal symptoms 
seemed to decrease with increasing age in both men 
and women (figure 3), no correlation could be shown (r = 
-0.22 in men, and r = -0.21 in women for age and upper 
abdominal symptoms; r = -0.19 in men, and r = -0.24 
in women for age and lower abdominal symptoms; all p 
values <0.01). 
Of all subjects taking either a PPI or an H2-receptor 
antagonist, 68% reported upper gastrointestinal 
symptoms and 55% reported lower gastrointestinal 
symptoms. Smoking and PPI use were associated with 
an increased risk for both upper and lower gastroin-
testinal symptoms (OR 1.99; 95% CI 1.56 to 2.55, and 
OR 1.37; 95% CI 1.01 to 1.75, respectively for smoking; 
and OR 3.17; 95% CI 2.17 to 4.72, and OR 2.14; 95% 
CI 1.49 to 3.08, respectively for PPIs). Excessive coffee 
consumption was associated with a decreased risk for 
upper and lower gastrointestinal symptoms (OR 0.75; 
95% CI 0.59 to 0.96, and OR 0.72; 95% CI 0.56 to 0.93, 
respectively). 
figure 1. Prevalence of upper gastrointestinal 
symptoms
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figure 2. Prevalence of lower gastrointestinal 
symptoms
0% 10% 30% 40% 60%
Incomplete
20% 50%
Steatorrhoea
Strong urgency
Frequently with pain
Constipation
Alternately solid or loose
Diarrhoea
Frequently hard
Mucous
Bloody
Melaena
Abnormal defecation
Flatulence
No decline after defecation
After fasting
Postprandial
In general
Abdominal pain
Abdominal rumbling
figure 3. Prevalence of upper and lower gastrointestinal 
symptoms in men and women with increasing age
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d i s C U s s i o N
The results of this large-sample study show that upper and 
lower gastrointestinal symptoms are very common in a 
general Western population. The vast majority of subjects 
experienced at least one gastrointestinal symptom in the 
past four weeks. Women reported more symptoms than 
men, and the number of symptoms seems to decrease with 
increasing age, regardless of gender. Smoking and use of 
PPIs were associated with the presence of gastrointestinal 
symptoms, and there was a negative association with 
excessive coffee consumption.
Other studies have investigated the prevalence of dyspeptic 
and irritable bowel syndrome-related symptoms before. These 
studies, performed since 1951, reported a prevalence ranging 
from 25 up to 40%, depending on the study population and 
symptom definition.2,4,18-20 Since these first data, several 
changes in factors associated with the treatment and 
development of gastrointestinal symptoms have taken place, 
such as altered treatment options, increasing bodyweight 
and altered lifestyle habits. It might be expected that this 
has influenced gastrointestinal symptom aetiology and, with 
that, prevalence. Indeed, in a recent study we showed that 
the prevalence of upper gastrointestinal disorders found at 
endoscopy had changed significantly over time compared with 
15 years previously.21 Unfortunately, the current data do not 
allow us to draw any conclusions on diagnoses, and there is no 
data available on these symptoms in a comparable population. 
Nevertheless, proportions of patients with symptoms are in 
concordance with proportions described in the earlier studies, 
and although aetiology and the prevalence of certain disorders 
may have changed, gastrointestinal symptoms are still a 
common phenomenon in the general population. 
PPIs and smoking were associated with an increased 
risk for both upper and lower gastrointestinal symptoms. 
Smoking has previously been associated with the 
development of gastrointestinal disorders,22,23 and our 
results show once again how important it is for healthcare 
workers to emphasise the importance of quitting for the 
prevention and control of symptoms. PPIs are currently 
among the most frequently prescribed drugs in the 
Netherlands and numbers are still increasing (source: GIP 
databank; 01-05-2007). Currently, a common approach 
in Western countries is to prescribe acid-suppressive 
drugs for upper gastrointestinal tract symptoms without 
suspicion of a malignancy.24 A large proportion of patients 
with upper gastrointestinal symptoms have no acid-related 
disorder underlying symptoms and it is therefore likely that 
a group of patients are taking acid-inhibiting medication 
without the expected effect on gastrointestinal symptoms.25 
It is very probable that the observed increased risk is 
a reflection of the large number of people using this 
medication without obtaining the desired effect, rather 
than a true association between the use of PPIs and 
symptom development. The association with lower 
gastrointestinal symptoms might be the result of common 
side effects of PPIs on the lower gastrointestinal tract, such 
as diarrhoea, constipation and flatulence.26 On the other 
hand, it is known that gastrointestinal symptoms are often 
hard to locate, and that upper and lower gastrointestinal 
symptoms often coexist.27 It is quite possible that many 
patients received a PPI for their upper gastro intestinal 
symptoms, while their lower gastrointestinal symptoms 
persisted. Regarding the inversed association with excessive 
coffee consumption, it is imaginable that subjects with 
gastro intestinal symptoms consume less coffee in order 
Table 2. Prevalence of specific characteristics among subjects with and without upper and lower gastrointestinal 
symptoms
Upper gastrointestinal symptoms lower gastrointestinal symptoms
Present
n=690 (43%)
Not present
n (%)
Adjusted* or 
(95% Ci)
Present
n=616 (38%)
Not present
n (%)
Adjusted* or 
(95% Ci)
Alcohol abuse 37 (5.4) 65 (7.0) 0.66 (0.43-1.02) 36 (5.8) 66 (6.6) 0.85 (0.55-1.30)
Excessive coffee consumption 156 (22.6) 227 (24.5) 0.75 (0.59-0.96) 130 (21.1) 253 (25.3) 0.72 (0.56-0.93)
Smoking 207 (30.0) 178 (19.4) 1.99 (1.56-2.55) 164 (26.6) 221 (22.3) 1.37 (1.01-1.75)
Medication
Aspirin 65 (9.4) 100 (10.8) 0.85 (0.60-1.19) 57 (9.3) 108 (10.8) 0.84 (0.59-1.18)
NSAID 36 (5.2) 30 (3.2) 1.37 (0.82-2.30) 28 (4.6) 38 (3.8) 1.05 (0.62-1.74)
Proton pump inhibitor 92 (13.3) 42 (4.5) 3.17 (2.17-4.72) 74 (12.0) 60 (6.0) 2.14 (1.49-3.08)
H2-receptor antagonist 11 (1.6) 6 (0.7) 2.63 (0.97-7.84) 10 (1.6) 7 (0.7) 2.52 (0.95-7.06)
BMI (kg/m2):
<18.5• 20 (2.9) 13 (1.4) 1.54 (0.64-3.80) 19 (3.1) 14 (1.4) 1.97 (0.83-4.78)
18.5-25• 326 (47.3) 488 (52.7) 0.65 (0.38-1.09) 297 (48.2) 517 (51.7) 0.81 (0.48-1.36)
25>• 310 (44.9) 394 (42.6) 0.74 (0.44-1.26) 272 (44.2) 432 (43.2) 0.87 (0.52-1.48)
*Adjusted for all other variables. Alcohol abuse: ≥14 units/week for women and ≥21 units/week for men. Excessive coffee consumption: ≥6 units/
day. smoking: any consumption of cigarettes or cigars. NsAid = non-steroid anti-inflammatory drug.
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to avoid symptoms, rather than that coffee itself has a 
protective effect for symptom development. 
The response rate to the self-report questionnaire was 
rather low, compared with the previously mentioned studies 
investigating symptom prevalence. The low response rate is 
most probably due to the voluntary, anonymous nature of 
this study: questionnaires were spread door-to-door, whereas 
other studies often used a clinical or outpatient setting to 
approach potential participants. This last method leads to 
higher response rates since people are more likely to fill in a 
questionnaire if asked to by a healthcare worker. Our purpose 
was to obtain insight into a general population, regardless 
of medical background or healthcare seeking behaviour. 
Therefore, response was dependent on individual willingness 
to complete the questionnaire, and response bias might have 
influenced our results. The investigated sample matched 
the general Dutch population for several demographic and 
socioeconomic factors (data from Statistics Netherlands 
(CBS)). However, the mean age of the responders was 
slightly higher, and there were more women than men. 
This would mean that our results could in fact represent an 
underestimation of prevalence because younger people report 
more symptoms, or that the higher proportion of women has 
caused an overestimation because women tend to report more 
symptoms. The truth probably lies somewhere in the middle; 
considering these contradicting influences on symptoms, 
the large sample size and the resemblance of our sample to 
the general Dutch population for other factors, it might be 
assumed that data about the prevalence of symptoms are 
representative for the general population as well. 
In summary, over the past decades, several changes in 
factors associated with the development and treatment of 
gastrointestinal disorders have taken place. The results 
of this study show that although these changes might 
have altered the aetiology and prevalence of underlying 
disorders, gastrointestinal symptoms are still very common 
in the general population. 
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